Cancer Biomarkers Market is projected to value over CAGR of over 12% during the forecast period 2022 to 2028.

Rising incidences of malignancies along with rising emphasis on developing targeted therapies is the key factor driving the market growth. Furthermore, the increasing awareness among healthcare personnel and patients regarding the importance of early malignancy diagnosis along with rising insistence for personalised medicine shall boost the cancer biomarkers market growth. Diagnostic biomarkers are used for early diagnosis that has enabled doctors on making better decisions regarding treatment alternatives resulting into successful recoveries in less time. Additionally, the increased rate of regulatory approvals of advanced diagnostics and drugs related to cancer biomarkers is predicted to increase the rate of adoption. For example, Epigenomics Inc. in 2016 announced its Epi proColon was added as an epigenetic biomarker test by the Chinese government for screening colorectal cancer.

Market Segmentation:

By Type
• Protein Biomarkers                
• Genetic Biomarkers
• Other Cancer Biomarkers (cell, viral, and carbohydrate biomarkers)
By Cancer Type
• Breast Cancer
• Lung Cancer
• Prostate Cancer
• Non-Hodgkin Lymphoma
• Melanoma
• Leukemia
• Thyroid Cancer
• Bladder Cancer
• Kidney Cancer
• Other Cancer Types    
By Profiling Technology
• OMICS Technologies
• Proteomics
• Genomics
  o NGS
  o PCR
• Other OMICS Technologies

• Imaging Technologies
  o Ultrasound
  o CT
  o MRI
  o PET
  o Mammography
• Immunoassays
• Cytogenetics
  o ISH
  o Other Cytogenetics-Based Tests
• Bioinformatics

By Application
• Diagnostics
• Research and Development
• Prognostics
• Risk Assessment
• Others

By Region
• North America
• Europe

• Asia-Pacific
• Latin America
• Middle East and Africa

The market is fragmented into type, cancer type, profiling technology, application and region. The type segment is categorised into protein biomarker and genetic biomarker. The genetic biomarker segment is anticipated to hold the largest cancer biomarkers market share, and this can be credited to the technological advancements in gene expression profiling, polymerase chain reaction and next generation sequencing for genetic biomarker diagnosis and discovery. The cancer type segment is categorised into breast cancer, lung cancer, CRC, prostate cancer, non-Hodgkin’s Lymhoma, melanoma, leukemia, thyroid cancer, bladder cancer, kidney cancer and other cancers. The lung cancer segment is predicted to account the largest cancer biomarkers market share. This growth can be credited to the rise in the number od newly registered cases of lung cancer. Companies are increasingly focusing on lung cancer biomarker research along with the rising comprehension of lung cancer morphology, rising emphasis om early cancer detection are boosting the proliferation of the market. The profiling technology segment is divided into OMICS technologies, proteomics, genomics. Bioinformatics is used for identifying biomedically relevant and powerful biomarkers. Data mining provides tools foe evaluating and interpreting the resulting predictions and models along with techniques for bolstering the prediction mechanisms. Such factors shall boost the proliferation of the market.

Regional Analysis:

The North America region is expected to lead the market owing to the increased adoption of novel technologies such as next generation sequencing, growing research studies for developing and discovering advanced biomarkers and a strong presence of major pharmaceutical players. Furthermore, increased public and private investments and funds and rising usage of biomarkers for stratifying patients and developing drugs.

Competitive Landscape:                           

The prominent players of the market are Thermo Fisher Scientific, Bio-Rad Laboratories, Roche Diagnostics, Qiagen N.V., Illumina, GE Healthcare, Agilent Technologies, Biomérieux SA, Merck & Co., Abbott Laboratories, Becton, Dickinson and Company, Danaher Corporation, Myriad Genetics, Sysmex Corporation, Hologic, Quest Diagnostics.

FutureWise Key Takeaways:

  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth

Objectives of the Study:

  • To provide with an exhaustive analysis on the global cancer biomarkers market by type, by cancer type, by profiling technology, by application and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions         

Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com


Need Assistance


UK : +44 141 628 9353
US : +1 347 709 4931


Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics